Oslo, 3 October 2025: Reference is made to the stock exchange announcement
published by Navamedic ASA (the "Company") on 22 September 2025, regarding the
commencement of the subscription period in the partly underwritten rights issue
of up to 6,046,511 new shares in the Company, at a subscription price of NOK
21.50 per share (the "Rights Issue") and the receipt of subscription rights in
the Rights Issue by certain primary insiders, and certain close associates of
primary insiders, of the Company.

The Company has been informed that certain primary insiders and certain close
associates of primary insiders have subscribed for new shares in the Rights
Issue:

Soleglad Invest AS, a company closely associated with Kathrine Elisabeth Gamborg
Andreassen, CEO of the Company, has subscribed for 23,260 new shares.

Jostein Davidsen, Chairperson of the Board of Directors of the Company, has
subscribed for 17,116 new shares.

Philip Sl√§tis, Commercial Director RX & International of the Company, has
subscribed for 3,422 new shares.

Tranbergkollen Invest AS, a company closely associated with Astrid T. Bratvedt,
Chief Scientific Officer of the Company, has subscribed for 25,000 new shares.

Jurs AS, a company closely associated with Morten Jurs, member of the Board of
Directors of the Company, has subscribed for 7,851 new shares.

Please see the attached forms for further details about the transactions.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.


